Pennisetum Purpureum in Sarcopenia Patients

Sarcopenia Clinical Trial

Official title: Effects of Pennisetum Purpureum Health Food Supplementation on Muscle Mass and Muscle Strength

Status Recruiting

Clinical Trial Summary

The purpose of this study was to investigate the effects of Pennisetum purpureum health food supplementation on muscle mass and muscle strength.

Clinical Trial Description

All participants performed anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey before supplementation. Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference. The definition of insufficient muscle mass was based on the Asian working group for sarcopenia (AWGS) that skeletal muscle mass in extremities by dual-energy X-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women is a necessary condition, and one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than12 seconds. The anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey, were collected after 8 weeks and 12 weeks of supplementation. ;

Related Conditions & MeSH terms

• Sarcopenia

• NCT number: NCT05911516
• Study type: Interventional
• Source: Taipei Medical University
• Contact: Ming Ta Yang, Doctorate
• Phone: 886-2-27361661
• Email: yangrugby@tmu.edu.tw
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2023
• Completion date: March 2024